Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated September 16, 2025.

Colorectal Cancer

Hepatocellular Cancer

Other Solid Tumors

Prostate Cancer

Thyroid Cancer

Types of Enhancements Available

Audio

Infographic

Plain Language Summary

Video

Other

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Shore N., et al. European Journal of Cancer. 2025;223:115513.

Shore N.; Morgans A.K.; Boegemann M.; Gallagher E.; Paracha N.; ,

READ

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study

Weinrib R., et al. Oncology and Therapy. 2025.

Weinrib R.; Fortuny J.; Martinez D.; Kollhorst B.; Haug U.; ,

READ

Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification

Vázquez-Estévez S., et al. Clinical Genitourinary Cancer. 2025;23(3):102338

Vázquez-Estévez S.; Gallardo E.; Fernández-Calvo O.; Juan-Fita M,

READ

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice

van Riel J.H.H.M.; Donswijk M.L.; Brouwer C.; Gerritsen W.R.; Ta,

READ

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Wallis C.J.D., et al. European Urology Oncology. 2025.

Wallis C.J.D.; Ekberg S.; Morgans A.K.; Boegemann M.; Parach,

READ

Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK

Goebell P.J., et al. Future Oncology. 2025;21(11):1377-1390.

Goebell P.J.; Chen S.; Jhaveri J.,

READ

Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage

Ibáñez C., et al. Expert Opinion on Drug Metabolism and Toxicology. 2025;21(6):625-636.

Ibáñez C.; Tourís-Lores M.; Montesa Á.; López-Campos F.; Río,

READ

Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel

Maldonado X., et al. Clinical and Translational Oncology. 2025;708595.

Maldonado X.; Boladeras A.; Gaya J.M.; Muñoz J.; Planas J.; ,

READ

177Lu-prostate-specific membrane antigen following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience

Verholen F, et al. J Nucl Med. 2021;63(3):410-414.

Verholen F,

READ

Radium-223 in combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Multi-centre, Phase 2 Open-label Study

McDermott RS, et al. Ther Adv Med Oncol. 2021;13:17588359211042691.

McDermott RS,

READ

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Site last updated 02/2026

Welcome to Bayer US Medical Affairs

Publications

Publications

Types of Enhancements Available

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study

Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK

Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage

Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel

177Lu-prostate-specific membrane antigen following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience

Radium-223 in combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Multi-centre, Phase 2 Open-label Study